The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / AbbVie’s Rheumatoid Arthritis Drug Succeeds in Late-Stage Trial

AbbVie’s Rheumatoid Arthritis Drug Succeeds in Late-Stage Trial

June 7, 2017 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—U.S. drugmaker AbbVie Inc said on Wednesday late-stage data showed its rheumatoid arthritis drug performed better than a placebo in reducing symptoms in moderate-to-severe patients who have not adequately responded to standard treatments.

You Might Also Like
  • AbbVie’s RA Drug Succeeds in Late Stage Study
  • Lilly’s Lupus Treatment Succeeds in Mid-Stage Trial
  • Pfizer-Lilly Pain Drug Meets Late-Stage Trial Goals

Two doses of the drug, upadacitinib, induced a statistically significant reduction in symptoms compared to a placebo in the 12-week long study, AbbVie said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Nearly half of the patients achieved low disease activity at both doses and around 30 percent achieved clinical remission, data showed.

Upadacitinib is a once-daily pill belonging to a class of drugs known as Jak inhibitors, which block inflammation-causing enzymes known as Janus kinases.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Jak inhibitors compete with injected biologics, including Amgen Inc’s top-selling Enbrel (etanercept), which in 2016 generated sales nearly $6 billion in sales. Other biologics include Pfizer Inc’s Xeljanz (tofacitinib citrate) and AbbVie’s Humira (adalimumab).

Last month, the U.S. Food and Drug Administration declined to approve Eli Lilly and Co and partner Incyte Corp’s rheumatoid arthritis drug, Olumiant (baricitinib).

AbbVie is also evaluating upadacitinib for several other conditions, including psoriatic arthritis, Crohn’s disease, ulcerative colitis and atopic dermatitis.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Filed Under: Rheumatoid Arthritis Tagged With: AbbVie Inc, JAK inhibitors, Rheumatoid Arthritis (RA), upadacitinib

You Might Also Like:
  • AbbVie’s RA Drug Succeeds in Late Stage Study
  • Lilly’s Lupus Treatment Succeeds in Mid-Stage Trial
  • Pfizer-Lilly Pain Drug Meets Late-Stage Trial Goals
  • Regeneron Pain Drug Clears Late-Stage Trial

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.